{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:13:46Z","timestamp":1791807226261,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ajog.2022.01.004","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T19:37:55Z","timestamp":1642016275000},"page":"263.e1-263.e38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2790-9938","authenticated-orcid":false,"given":"Amir","family":"Sarayani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-6526","authenticated-orcid":false,"given":"Yasser","family":"Albogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy Nhu","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0866-4579","authenticated-orcid":false,"given":"Nicole E.","family":"Smolinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-2603","authenticated-orcid":false,"given":"Sabina","family":"Nduaguba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-4928","authenticated-orcid":false,"given":"Sonja A.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6518-5961","authenticated-orcid":false,"given":"Almut G.","family":"Winterstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2022.01.004_bib1","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1177\/1049732317732027","article-title":"Improving safe use of medications during pregnancy: the roles of patients, physicians, and pharmacists","volume":"27","author":"Lynch","year":"2017","journal-title":"Qual Health Res"},{"key":"10.1016\/j.ajog.2022.01.004_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2010.09976.x","article-title":"Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review","volume":"164","author":"Crijns","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ajog.2022.01.004_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1177\/2168479013516776","article-title":"Teratogenic drugs and risk management: an implementation assessment","volume":"48","author":"Freeman","year":"2014","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.ajog.2022.01.004_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajog.2021.02.032","article-title":"Prescription medications for use in pregnancy-perspective from the US Food and Drug Administration","volume":"225","author":"Wesley","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.01.004_bib5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: history and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res C Embryo Today"},{"issue":"Suppl1","key":"10.1016\/j.ajog.2022.01.004_bib6","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.drugalcdep.2009.02.007","article-title":"Risk management of drug products and the U.S. Food and Drug Administration: evolution and context","volume":"105","author":"Leiderman","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.ajog.2022.01.004_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.sapharm.2013.03.005","article-title":"Examination of risk evaluation and mitigation strategies and drug safety in the US","volume":"10","author":"Rodriguez-Monguio","year":"2014","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.ajog.2022.01.004_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1089\/pop.2012.0021","article-title":"Risk evaluation mitigation strategies: the evolution of risk management policy","volume":"16","author":"Hollingsworth","year":"2013","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.ajog.2022.01.004_bib9","unstructured":"Food and Drug Administration (FDA). Standardizing and evaluating risk evaluation and mitigation strategies (REMS) public meeting-background materials; 2013. https:\/\/www.fda.gov\/industry\/prescription-drug-user-fee-amendments\/background-materials-rems-standardization-and-evalution-public-meeting."},{"key":"10.1016\/j.ajog.2022.01.004_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15094","article-title":"Evaluation of drug labels following the 2015 pregnancy and lactation labeling rule","volume":"3","author":"Byrne","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ajog.2022.01.004_bib11","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.clinthera.2016.11.007","article-title":"The US Food and Drug Administration\u2019s risk evaluation and mitigation strategy (REMS) program - current status and future direction","volume":"38","author":"Wu","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.ajog.2022.01.004_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2019.20288","article-title":"FDA approval and regulation of pharmaceuticals, 1983-2018","volume":"323","author":"Darrow","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2022.01.004_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/bmjqs-2019-010588","article-title":"REMS in pregnancy: system perfectly designed to the get the results it gets","volume":"29","author":"Zipursky","year":"2020","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib14","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/pds.3481","article-title":"Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States","volume":"22","author":"Pinheiro","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40264-016-0501-2","article-title":"Effectiveness of risk evaluation and mitigation strategies (REMS) for lenalidomide and thalidomide: patient comprehension and knowledge retention","volume":"40","author":"Brandenburg","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1001\/jamadermatol.2013.6862","article-title":"Women\u2019s experiences with isotretinoin risk reduction counseling","volume":"150","author":"Werner","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ajog.2022.01.004_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jaad.2010.09.017","article-title":"The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system","volume":"65","author":"Shin","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ajog.2022.01.004_bib18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/bmjqs-2019-010098","article-title":"Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate","volume":"29","author":"Sarayani","year":"2020","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib19","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajmg.c.30313","article-title":"Evolving knowledge of the teratogenicity of medications in human pregnancy","volume":"157C","author":"Adam","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.ajog.2022.01.004_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/AOG.0000000000000982","article-title":"The most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program","volume":"126","author":"Palmsten","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.01.004_bib21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/pds.5017","article-title":"Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: a retrospective cohort study","volume":"29","author":"Thai","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2147\/CLEP.S269400","article-title":"Impact of the transition from ICD-9-CM to ICD-10-CM on the identification of pregnancy episodes in US health insurance claims data","volume":"12","author":"Sarayani","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ajog.2022.01.004_bib23","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1475-6773.2006.00635.x","article-title":"Development of an algorithm to identify pregnancy episodes in an integrated health care delivery system","volume":"42","author":"Hornbrook","year":"2007","journal-title":"Health Serv Res"},{"key":"10.1016\/j.ajog.2022.01.004_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192033","article-title":"Inferring pregnancy episodes and outcomes within a network of observational databases","volume":"13","author":"Matcho","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2022.01.004_bib25","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/pds.5126","article-title":"Validation of algorithms to estimate gestational age at birth in the Medicaid Analytic eXtract-Quantifying the misclassification of maternal drug exposure during pregnancy","volume":"29","author":"Zhu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib26","doi-asserted-by":"crossref","unstructured":"Institute of Medicine (US) Committee on Unintended Pregnancy; Brown SS, Eisenberg L, editors. The Best Intentions: Unintended Pregnancy and the Well-Being of Children and Families. Washington (DC): National Academies Press (US); 1995. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK232127\/. https:\/\/doi.org\/10.17226\/4903.","DOI":"10.17226\/4903"},{"key":"10.1016\/j.ajog.2022.01.004_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMsa1506575","article-title":"Declines in unintended pregnancy in the United States, 2008-2011","volume":"374","author":"Finer","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.01.004_bib28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/00005650-199807000-00016","article-title":"Casemix adjustment of managed care claims data using the clinical classification for health policy research method","volume":"36","author":"Cowen","year":"1998","journal-title":"Med Care"},{"key":"10.1016\/j.ajog.2022.01.004_bib29","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/pds.1550","article-title":"Outpatient use of cardiovascular drugs during pregnancy","volume":"17","author":"Andrade","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1161\/HYPERTENSIONAHA.112.197095","article-title":"Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population","volume":"60","author":"Bateman","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ajog.2022.01.004_bib31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/pds.1235","article-title":"Use of prescription medications with a potential for fetal harm among pregnant women","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib32","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.284.13.1670","article-title":"Quality of medical care delivered to medicare Beneficiaries: a profile at state and national levels","volume":"284","author":"Jencks","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2022.01.004_bib33","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jama.281.7.627","article-title":"Geographic variation in the treatment of acute myocardial Infarction: the cooperative cardiovascular project","volume":"281","author":"O\u2019Connor","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2022.01.004_bib34","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/archinternmed.2012.3717","article-title":"Geographic variation in outpatient antibiotic prescribing among older adults","volume":"172","author":"Zhang","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajog.2022.01.004_bib35","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ajog.2014.05.040","article-title":"Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention--convened meeting","volume":"211","author":"Broussard","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.01.004_bib36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/pds.3410","article-title":"Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011","volume":"22","author":"Peters","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib37","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.jaip.2020.01.056","article-title":"Clinicians\u2019 perspective of the new pregnancy and lactation labeling rule (PLLR): results from an AAAAI\/FDA survey","volume":"8","author":"Namazy","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.ajog.2022.01.004_bib38","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.japh.2018.12.011","article-title":"The critical need for clinical decision support systems for identification and management of teratogenic medications","volume":"59","author":"DiPietro Mager","year":"2019","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.ajog.2022.01.004_bib39","unstructured":"Smith M, Morrato E, Sun S, et\u00a0al. ISPE RESPONSE TO FDA QUESTIONS- standardization and evaluation of risk evaluation and mitigation strategies (REMS)\u2014public meeting; 2013. https:\/\/www.pharmacoepi.org\/pub\/?id=C62134BB-AD3F-1AFF-FABA-25C83413971E."},{"key":"10.1016\/j.ajog.2022.01.004_bib40","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/pds.3480","article-title":"A\u00a0critical review of methods to evaluate the impact of FDA regulatory actions","volume":"22","author":"Briesacher","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40264-020-00905-8","article-title":"Quality of reporting on the evaluation of risk minimization programs: a systematic review","volume":"43","author":"Russell","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s40264-014-0197-0","article-title":"Advancing the field of pharmaceutical risk minimization through application of implementation science best practices","volume":"37","author":"Smith","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.ajog.2022.01.004_bib43","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2105\/AJPH.2016.303133","article-title":"Patterns of health insurance coverage around the time of pregnancy among women with live-born infants--pregnancy risk assessment monitoring system, 29 States, 2009","volume":"106","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1016\/j.ajog.2022.01.004_bib44","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ajmg.c.30313","article-title":"Evolving knowledge of the teratogenicity of medications in human pregnancy","volume":"157C","author":"Adam","year":"2011","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.ajog.2022.01.004_bib45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/AOG.0000000000000982","article-title":"The most commonly dispensed prescription medications among pregnant women enrolled in the U.S. Medicaid program","volume":"126","author":"Palmsten","year":"2015","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.01.004_bib46","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/j.1471-0528.2009.02377.x","article-title":"Prescriptions filled during pregnancy for drugs with the potential of fetal harm","volume":"116","author":"Kulaga","year":"2009","journal-title":"BJOG"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:37:11Z","timestamp":1757590631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937822000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0002937822000084"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2022.01.004","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2022.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}